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Abstract
Immunogenicity of biopharmaceutical products in multiple sclerosis is a frequent side effect
which has a multifactorial etiology. Here we study associations between anti-drug antibody
(ADA) occurrence and demographic and clinical factors. Retrospective data from routine
ADA test laboratories in Sweden, Denmark, Austria and Germany (Dusseldorf group) and
from one research study in Germany (Munich group) were gathered to build a collaborative
multi-cohort dataset within the framework of the ABIRISK project. A subset of 5638 inter-
feron-beta (IFNβ)-treated and 3440 natalizumab-treated patients having data on at least
the first two years of treatment were eligible for interval-censored time-to-event analysis. In
multivariate Cox regression, IFNβ-1a subcutaneous and IFNβ-1b subcutaneous treated
patients were at higher risk of ADA occurrence compared to IFNβ-1a intramuscular-treated
patients (pooled HR = 6.4, 95% CI 4.9–8.4 and pooled HR = 8.7, 95% CI 6.6–11.4 respec-
tively). Patients older than 50 years at start of IFNβ therapy developed ADA more fre-
quently than adult patients younger than 30 (pooled HR = 1.8, 95% CI 1.4–2.3). Men
developed ADA more frequently than women (pooled HR = 1.3, 95% CI 1.1–1.6).
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Interestingly we observed that in Sweden and Germany, patients who started IFNβ in April
were at higher risk of developing ADA (HR = 1.6, 95% CI 1.1–2.4 and HR = 2.4, 95% CI
1.5–3.9 respectively). This result is not confirmed in the other cohorts and warrants further
investigations. Concerning natalizumab, patients older than 45 years had a higher ADA
rate (pooled HR = 1.4, 95% CI 1.0–1.8) and women developed ADA more frequently than
men (pooled HR = 1.4, 95% CI 1.0–2.0). We confirmed previously reported differences in
immunogenicity of the different types of IFNβ. Differences in ADA occurrence by sex and
age are reported here for the first time. These findings should be further investigated taking
into account other exposures and biomarkers.
Introduction
The introduction of biotechnology-derivedproteins (BPs) has been a critical step forward in
the treatment of multiple sclerosis (MS), with BPs such as interferon beta (IFNβ) registered
since the 1990s and natalizumab available since 2006 in the EU. Natalizumab is mainly used as
a second line treatment for patients with relapsing-remitting MS (RRMS) that do not respond
to treatment with first line drugs such as IFNβ. Failure of response to therapy may occur due to
an unwanted immune response against the BP. This immunological reaction to BPs is not fully
understood and the fraction of patients developing anti-drug antibodies (ADA) has varied
from 2 to 47%, depending upon either the product or the laboratorymethods and cut-off used
to define antibody positivity [1].
The consequences of this immunological reaction range from transient ADA to high titer
ADA with clear clinical effects [2,3]. In particular, the occurrence of ADA may decrease the
efficacyof BPs by neutralizing their activity or modifying their drug clearance and ADA may
also be associated with BP-specific hypersensitivity reactions [4]. Clinically relevant neutraliz-
ing ADA (NAbs) against IFNβ usually develop between 9 and 18 months after start of therapy
[5]. Patients who have been persistently NAb negative during the first 2 years of IFNβ therapy
only rarely becomeNAb positive [6]. For natalizumab, the antibodies are detected in approxi-
matively 9% of treated patients with 3% that are transient [7]. These ADA develop quickly,
within 4 months following the first infusion of treatment [8]. In establishing the used ADA
assay, the cut-point set for ADA positivity by enzyme-linked immunosorbent assay (ELISA)
correspond to neutralizing antibody positive by flow cytometry blocking assay [7].
Many factors (patient-, disease- or product-related) may influence the risk of BP immuno-
genicity but the relative contribution of these factors to the development of ADA is not cur-
rently understood. The ability to identify patients at high risk for ADA and subsequent lack of
treatment efficacy or hypersensitivity reactions would allow better personalized therapy. The
immunogenic potential of BPs can only be definitively assessed in human studies. Previous
investigations have identified oligoclonal band negativity as a protective factor [9], specific
HLA haplotypes as risk factors for IFNβADA [10–13], and smoking as a risk factor for both
IFNβ and natalizumab ADA [7–9].
In order to carry out an unbiased evaluation of the relationships between bio-clinical factors
and the occurrence of ADAs, we selected a target population that was extracted from the whole
ABIRISK tranSMART database based on five European MS cohorts and that is composed by
BP naive adult patients with biological samples being taken within the first two years of
treatment.
The present study gathers data from four European central laboratories and one research
center routinely performingADA tests in order to identify patient-related and treatment-
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Patients and Methods
Patients
The present study is a collaborative analysis of historical data collected from a number of Euro-
peanMS cohorts under the leadership of the ABIRISK EU-consortium, standardized into a
common format and grouped into the ABIRISK tranSMART database including data from
national routine ADA test laboratories in Sweden, Denmark, Austria and Germany (Dussel-
dorf group) and from one research study in Germany (Munich group).
In Sweden, Germany and Denmark an ethical permission for the analysis of anonymized
patient retrospective data was required. For the Swedish cohort the study was approved by the
Regional Ethics Committee in Stockholm, Sweden (http://www.epn.se/en/start/the-
organisation/), and approval for export of data from the national Multiple Sclerosis Registry
(MSreg) was given by the Research Board of the Swedish MS Society. For the German cohorts,
the study was approved by the Ethics Committee of the School of Medicine of the Technical
University of Munich and the Ethics Committee of the medical faculty of the University of
Dusseldorf. The Danish MS-cohort collected in the Danish Multiple Sclerosis Biobank was
approved by the Regional Scientific Ethics Committee in Copenhagen and Frederiksberg,Den-
mark, and approval for use of data was given by the Danish Data Protection Agency in the
Capital Region, Denmark. In Austria the Ethics Committee judged that for retrospective analy-
ses based on anonymized data that were collected during routine procedures, an ethical
approval was not required.
In total the database contained 20,465 patients from the four countries and ADA data of
42,843 samples together with treatment history, type of ADA assay, age and sex. Data about
anti-natalizumab ADA tests were available only in reference laboratories from Sweden, Austria
and Denmark.
Populations eligible for inclusion in the IFNβ and natalizumab historical longitudinal analy-
ses were selected based on the following criteria: (i) for IFNβ, naive to IFNβ prior to the IFNβ
for which the first NAb test is available, (ii) for IFNβ and natalizumab, date of first BP dose
administration known (at least with a month precision), (iii) for IFNβ, at least one NAb test
result available after first dose and before 24 months of treatment, (iv) for natalizumab, at least
one ADA test result available after baseline and before 12 months of treatment, and (v) for
IFNβ and natalizumab, age at date of first BP dose more than 18 years.
Due to the low sample size obtained from the Swiss and Spanish cohorts, we focused on the
cohorts from Sweden, Austria, Denmark, and Germany (Dusseldorf and Munich groups).
IFNβ-treatedMS patients tested for ADA from 2002 to 2013 in Sweden, from 1996 to 2014 in
Austria, from 2009 to 2014 in Denmark, from 2008 to 2014 in the German reference laboratory
(Dusseldorf group) and from 2005 to 2008 in the German research study (Munich group) were
included in the time-to-event analysis. Eligible natalizumab-treated patients were tested from
2006 to 2013 in Sweden, from 2007 to 2014 in Austria and from 2007 to 2014 in Denmark.
The ABIRISK tranSMART database
The ABIRISK database integrates immunogenicity data from a number of European countries in
a well-structured format. The data is harmonized over different cohorts and the format is based
on the CDISC standards (http://www.cdisc.org/).Where no previous variable description can be
found in CDISC, a local variable description is used. Data was prepared by data custodians using
a data load plan describing the variable semantics and format. Anonymized data was uploaded
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PLOS ONE | DOI:10.1371/journal.pone.0162752 November 2, 2016 3 / 19
lecturing, travel expenses for attending meetings,
and financial support for research from Bayer
Health Care, Biogen Idec, Genzyme/Sanofi Aventis,
Grifols, Merck Serono, Mitsubishi Europe,
Novartis, Roche, Talecris, and TEVA. B. Hemmer
has served on scientific advisory boards for Roche,
Novartis, Bayer Schering, Merck Serono, Biogen
Idec, GSK, Chugai Pharmaceuticals, Micromet,
Genentech and Genzyme Corporation; serves on
the international advisory board of Archives of
Neurology and Experimental Neurology; has
received speaker honoraria from Bayer Schering,
Novartis, Biogen Idec, Merck Serono, Roche, and
Teva Pharmaceutical Industries Ltd; and has
received research support from Biogen Idec, Bayer
Schering, Merck Serono, Five prime, Metanomics,
Chugai Pharmaceuticals and Novartis. He has been
filed a patent for the detection of antibodies and T
cells against KIR4.1 in a subpopulation of MS
patients and genetic determinants of neutralizing
antibodies to interferon-beta. P.S. Sørensen has
served on scientific advisory boards for Biogen
Idec, Merck Serono, Novartis, Genzyme, Teva
Pharmaceutical Industries Ltd., GlaxoSmithKline,
medDay Pharmaceuticals and Forward Pharma;
has been on steering committees or independent
data monitoring boards in clinical trials sponsored
by Merck Serono, Teva Pharmaceutical Industries
Ltd., and GlaxoSmithKline; and has received
speaker honoraria from Biogen Idec, Merck
Serono, Teva Pharmaceutical Industries Ltd.,
Genzyme, and Novartis. His department has
received research support from Biogen Idec, Bayer
Schering, Merck Serono, TEVA, Baxter, Sanofi-
Aventis, BioMS, Novartis, Bayer, RoFAR, Roche,
Genzyme, from the Danish Multiple Sclerosis
Society, the Danish Medical Research Council, and
the European Union Sixth Framework Programme:
Life sciences, Genomics and Biotechnology for
health. M. Ryner has received research support
from Biogen Idec and Sanofi-Aventis, and received
speaker honoraria from Biogen Idec. Andy Lawton
and Dan Sikkema are employed by
GlaxoSmithKline. At the time of writing Julie
Davidson was employed by and held stocks/shares
in GlaxoSmithKline. Naoimh Donnellan is employed
by IPSEN. Agnès Hincelin-Mery is employed by
Sanofi. Pierre Do¨nnes is an employee of SciCross
AB and has received support from the Innovative
Medicines Initiative Joint Undertaking under grant
agreement No. [115303], resources of which are
composed of financial contribution from the
European Union’s Seventh Framework Program
(FP7/2007–2013) and EFPIA companies’ in kind
contribution. All the company-employed authors
declare that this does not alter their adherence to
PLOS ONE policies on sharing data and materials.
into the ABIRISK database, which is based on the tranSMART platform [14]. The tranSMART
platform is an open-source knowledgemanagement platform for translational science, supported
by a large number of organizations (http://www.transmartfoundation.org/). tranSMART pro-
vides tools to explore data, select specific cohorts and do basic statistics. It is also possible to
export data for further analysis in tools like SAS and R.
Biological samples testing
The reference laboratories received serum samples for analysis of neutralizing antibodies.
According to the countries, ADA screening was either mandatory for all BP-treated MS
patients as in Denmark since 1996, sponsored by the pharmaceutical companies and so widely
performed as in Sweden from 2003 to 2006 (thereafter performed ad hoc at the request of the
neurologists) or always performed ad hoc at the request of the neurologists as in Austria and
Germany (Dusseldorf).In the Munich study, ADA testing was performed in one single
instance for research purposes during an outpatient visit in the period 2003 to 2008.
In each laboratory, different methods to analyze ADA against IFNβwere used. Some labora-
tories search for both binding ADA and NAbs (Austria, Germany, Denmark) while others only
tested for NAbs (Sweden). Since these latter are more frequently persistent and clinically rele-
vant than binding ADA, in the present study only ADA determined to be NAbs against IFNβ
were considered.
In Sweden, three different NAb assays were performed across time: patient samples sent to
the laboratory in 2003–2006 were analyzed with the myxovirus resistance protein A (MxA) assay
(MPA) [15] while later samples were analyzed with theMxA gene expression assay (MGA)
[16,17]. Since 2012, samples were analyzed with the commercially available iLite anti-Human
IFNβ-1a bioassay (Biomonitor/Eurodiagnostica). In a recent publication a strong correlation of
NAb titers was found on a series of 118 serum samples titrated with theMPA and theMGA
assay in the Swedish central laboratory [12]. There were also significant correlations between
NAb titer levels measured withMGA and iLite [18]. For the three assays, titers were adjusted
using the Kawade formula [19]. NAb-positive screening samples were further titrated and NAb
titers were expressed as 10-fold reduction units per milliliter (TRU/ml) and the patients were
classified according to the following categories: negative (<10 TRU/ml), low positive ( 10–50
TRU/ml), medium positive (>50–200 TRU/ml), and high positive (>200 TRU/ml).
In Austria, three different NAb assays were also performed across time: the MPA and the
MGA assays, as well as the Luciferase assay (LUC) where NAb were measured using human
fibrosarcoma cells that express IFN-β receptors on their surface and were stably transfected
with a luciferase reporter gene cassette [20,21]. The cut-off for positivity for all NAb-tests
(MPA, MGA and LUC) was 20 TRU/ml, whereby 20–99 TRU/ml were considered low positive
and titers beginning from 100 TRU/ml high positive.
In Denmark, only results from the LUC method were applied. NAb-positivity was defined
by a titer 20 TRU/ml.
In Dusseldorf, ADA were first screened in the ELISA. Then NAbs were usually only tested
with LUC in case of a positive ADA testing. The patients were classified according to the fol-
lowing categories: negative (<20 TRU/ml), low positive ( 20–100 TRU/ml) and high positive
(>100 TRU/ml).
In Munich, ADA were first tested using a capture ELISA as describedby Pachner et al. [22].
Next antibodies were defined as NAb if MxA induction was decreased by more than 50% com-
pared with newly treated antibody-negative control donors. A cross-validation study on 247
samples was performed betweenAustria and Munich and has shown an agreement of 96% for
Anti-Drug Antibodies Occurrence in Multiple Sclerosis
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classifying samples in NAb positive (>30 TRU/ml) versus NAb negative (personal communi-
cation from F. Deisenhammer).
In our analyses, to define clinically relevant NAb-positivity against IFNβ, we kept the cut-
off used in each reference laboratory (200 TRU/ml in Sweden,100 TRU/ml in Austria,20
TRU/ml in Denmark,100 TRU/ml in Germany–Dusseldorf, and>50% inhibition in
Munich).
Concerning natalizumab, the same assay method undergoing regular proficiency testing
was used in Sweden, Austria and Denmark. Antibodies were measured using a bridging ELISA
method as described in the Biogen Idec protocol [7].
For ease of reading, we use "ADA" as a generic term in the remainder of the text for either
NAbs concerning IFNβ-treated patients or ELISA-detected ADA concerning natalizumab-
treated patients.
ADA outcome
In this work, we focused on a two-year ADA occurrencewindow after the start of therapy. To
take into account that ADA occurrence is a dynamic event which appears mainly within this
two-year window but can be censored, we performed time-to-event analyses. The outcome was
the time between the date of the first BP dose and the first time of ADA occurrence (positive
ADA). Patients without ADA occurrencewere censored at the date of their last clinic visit, the
end of treatment or at the last visit before a drug switch.
In practice, the ADA occurrence process was not under continuous monitoring. As a conse-
quence, a positive ADA result indicated that ADA have been produced during a particular
time interval but the exact event time of the ADA occurrencewas unknown.We only knew
that it occurred between two time points: the time of the last negative laboratory test and the
time of the first positive laboratory test. For the analyses, we considered interval-censored sur-
vival methods that explicitly took into account the information obtained for each patient.
Statistical analysis
For both therapies IFNβ and natalizumab, we present results of separate analyses in each
cohort and pooled analysis.
The non-parametric estimator for the cumulative probability distribution function under
interval censoring was computed as the complement of the survival estimator obtained using
the self-consistency or Turnbull’s algorithm [23]. The cumulative probability distribution func-
tion curveswere plotted for each BP (IFNβ and natalizumab separately) and according to cate-
gorical variables (type of therapy, age group, gender, month of first treatment and month of
birth). In order to compare these curves, p-values for rank-based tests adapted for interval cen-
soring [23–25] are presented.
For the univariate and multivariate analyses, we considered the Cox proportional hazards
model via a multiple imputation strategy for the unobserved survival times as proposed by Pan
[26].
Univariate Cox model analyses were carried out to assess the influence of clinical variables
on the time of occurrence of ADA. Hazard ratios (HR) and 95% confidence intervals (CIs)
were determined and reported.We investigated the impact of age, sex, month of therapy start
and month of birth. Previous IFNβ therapy before natalizumab were also explored (last IFNβ
taken, first IFNβ taken, last ADA status during IFNβ therapy, total duration of IFNβ therapy
and number of different IFNβ therapies).
All variables associated with the time to ADA occurrence in univariate analysis (with p-
value less than 0.20) were considered for the multivariate analysis using the Cox proportional
Anti-Drug Antibodies Occurrence in Multiple Sclerosis
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hazards model. Hazard ratios (HR) and 95% confidence intervals (CIs) were determined and
reported.
Analyses were performed using R software (version 3.0.2 software) with "interval", "Icens"
and "MIICD" packages.
Results
The flowchart (Fig 1) gives the details of the patients eligible in each cohort according to the
chosen inclusion criteria for IFNβ and natalizumab.
Among the 17,631 available IFNβ-treated patients in the database, 5,638 eligible patients
(32%) were considered for the survival analysis. For natalizumab, the pooled eligible cohort
consisted of 3,440 patients (85% of the patients available in the database).
We compared included patients treated with IFNβ to those not included with respect to age at
therapy start, sex, type of first IFNβ and ADA status for the first test performed. Regarding the
BPs, the fraction of included patients was higher for IFNβ-1a intramuscular (i.m.) as compared
to the other type of treatment (S5 Table). There was also a significant difference in age at start of
therapy in Germany-Dusseldorf (fewer patients older than 40 were included) and ADA status at
first visit differed between included and excluded in Sweden, Austria and Germany-Dusseldorf
(S5 Table). Concerningnatalizumab-treated patients, a lower proportion was excluded. They did
not differ from included patients, except for ADA status at first test available in Sweden: more
excluded patients were ADA positive. In most of the cases, this first test is a pre-treatment sam-
ple. All the patients with baselineADA positive tests were excluded from analysis.
In this selected historical cohort, the median number of tests for ADA against IFNβ done
for one patient was 2 (max = 7) in Sweden, 2 (max = 41) in Austria, 2 (max = 7) in Denmark, 1
(max = 7) in Germany—Dusseldorf group, and 1 in Germany–Munich group (current status
data). Concerning natalizumab, the median number of ADA tests done for one patient was 4
(max = 10) in Sweden, 2 (max = 50) in Austria, and 3 (max = 9) in Denmark.
In the reference laboratories, the first IFNβADA test was performed around one year after
first dose of therapy in Sweden, Austria and Germany, and 6 months after first dose of therapy
in Denmark. Thereafter tests were done approximatively every 6 months in each country.
Fig 1. Inclusion flow chart. Flow chart of patients by country for IFNβ (left side) and natalizumab (right side) treated patients.
doi:10.1371/journal.pone.0162752.g001
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Concerning natalizumab, time interval between two visits was approximatively from 3 to 6
months.
Univariate analyses
Results for IFNβ. According to the univariate analyses, the type of IFNβ treatment was
strongly associated with the rate of ADA occurrence (p< 0.0001 in each cohort) (Fig 2).
As expectedmost of the ADA occurredwithin two years of IFNβ therapy. Of the two differ-
ent routes of administration for IFNβ-1a, the one with a single weekly intramuscular (i.m.)
dose was less immunogenic with 1.1 to 4.2% (95% confidence intervals (CI) ranging from 0 to
6.8%) of the patients who developedADA before 18 months of therapy as compared to 11.1 to
23.0% (95% CI ranging from 1.0 to 30.7%) for the patients with three weekly subcutaneous (s.
c.) doses (Table 1). Patients treated with IFNβ-1b s.c. every other day had an even higher rate
Fig 2. Cumulative probability of developing anti-IFNβ ADA. Estimated cumulative probability of developing
anti-IFNβ ADA by cohort and by categorical variables with p-values for rank-based tests adapted for interval
censoring.
doi:10.1371/journal.pone.0162752.g002
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of ADA development before 18 months of therapy: 17.4 to 33.3% (95% CI ranging from 0 to
51.7%).
Looking to all the cumulative probability curves across the countries, we observedvery simi-
lar rates of ADA development by type of IFNβ-therapy.
Age at start of IFNβ-therapy was associated with immunogenicity in each country
(p< 0.01) with the exception of Germany (Dusseldorf group: p = 0.45; Munich group:
p = 0.08). Older patients had an increased risk of ADA. In Austria, Germany and Denmark,
male patients had an immune response to IFNβmore frequently than females, this association
between sex and ADA being significant in Austria and in Germany–Munich group (p< 0.01),
and borderline significant for Denmark (p = 0.06). This relationship did not reach significance
for Germany–Dusseldorf group (p = 0.09) and Sweden (p = 0.14). When comparing by period
of treatment start, patients who started IFNβ therapy in April were at higher risk of developing
ADA compared to patients who started at any other month in Germany (p< 0.0001 in Dussel-
dorf-group, and p = 0.07 in Munich-group). This association was not significant in Sweden
(p = 0.15) and in Denmark (p = 0.48). Conversely, in Austria, patients who started IFNβ ther-
apy in April were at lower risk of developing ADA (p = 0.04).
The month of birth was not associated with ADA development in any of the studied
cohorts.
The ADA assay methods which have changed across time in Sweden and Austria were asso-
ciated with ADA occurrence, suggesting a difference in the sensitivity of the assays as previ-
ously reported [18]. The MPA method detected a higher rate of ADA with 20% (95% CI 14.7–
25.1) of the patients who developedADA before 18 months of therapy in Austria and 30.3%
(95% CI 18.6–36.1) in Sweden, while 7% (95% CI 1.3–10.7) developedADA with the MGA
Table 1. Estimated cumulative probabilities with 95% confidence interval of ADA development before 18 months of IFNβ therapy.
Sweden Austria Germany (Dusseldorf) Denmark Germany (Munich)
(cut-off = 200 TRU/mL) (cut-off = 100 TRU/mL) (cut-off = 100 TRU/
mL)
(cut-off = 20 TRU/mL)
(N = 1830) (N = 1633) (N = 1086) (N = 634) (N = 455)
n % 95% CI n % 95% CI n % 95% CI n % 95% CI n % 95% CI
Type of IFNβ-1a i.m. 877 2.1 [0.0–3.4] 607 2.0 [0.7–5.3] 308 3.3 [0.0–6.4] 438 4.2 [0.0–6.8] 130 1.1 [0.0–3.6]
IFNβ IFNβ-1a s.c. 461 22.3 [13.4–25.5] 592 15.0 [9.7–19.9] 380 16.7 [8.2–20.7] 165 23.0 [14.5–30.7] 154 11.1 [1.0–16.9]
IFNβ-1b s.c. 492 21.1 [15.0–26.2] 434 22.8 [16.4–27.0] 398 17.4 [10.0–20.6] 31 33.3 [0.0–51.7] 171 22.4 [14.5–32.0]
Age at 18–30 389 9.9 [5.4–14.7] 491 9.3 [6.0–11.7] 373 11.9 [5.7–15.3] 150 13.0 [5.0–19.5] 30 12.5 [4.3–22.5]
baseline 30–40 551 10.3 [3.2–13.2] 574 11.8 [7.8–15.4] 339 13.1 [6.8–16.9] 219 6.6 [2.7–11.7] 146 8.5 [2.7–16.4]
40–50 564 13.5 [4.4–16.7] 416 18.2 [12.4–25.4] 263 9.6 [3.6–13.4] 179 11.2 [7.9–19.2] 150 12.2 [0.0–17.8]
50+ 326 14.4 [8.3–19.1] 152 25.0 [12.2–33.0] 111 15.8 [5.9–26.7] 83 18.8 [12.3–37.4] 129 25.9 [0.0–40.7]
Sex Female 1292 11.7 [9.2–13.5] 1136 12.6 [9.8–15.1] 782 12.0 [6.9–14.6] 460 11.6 [7.8–14.2] 333 7.8 [0.0–10.6]
Male 538 10.9 [6.1–14.6] 496 16.9 [10.4–21.1] 300 13.7 [5.3–18.3] 187 13.9 [0.0–25.5] 122 18.2 [8.9–29.4]
Month of April 168 13.5 [4.5–18.7] 162 11.3 [0.8–17.4] 94 27.3 [9.3–38.4] 53 17.4 [0.0–28.9] 31 18.5 [6.6–14.6]
start Other months 1662 12.2 [9.5–14.0] 1471 14.0 [13.0–19.4] 992 10.9 [7.6–13.5] 581 10.8 [7.8–14.8] 424 10.5 [8.2–45.4]
Month of April 181 13.7 [1.6–20.4] 145 13.0 [6.1–18.4] data not available 54 13.9 [0.0–25.5] 34 14.3 [0.0–33.3]
birth Other months 1649 10.9 [7.7–13.0] 1488 13.7 [11.5–16.3] 580 11.6 [7.8–14.2] 421 11.1 [0.0–13.6]
Assay MPA 362 30.3 [18.6–36.1] 631 20.0 [14.7–25.1]
method MGA 1199 8.4 [6.9–10.6] 256 7.0 [1.3–10.7]
LUC 754 11.0 [8.0–14.6]
iLite 269 4.0 [0.7–7.4]
doi:10.1371/journal.pone.0162752.t001
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method in Austria and 8.4% (95% CI 6.9–10.6) in Sweden. Concerning the more recent assay
methods, 11% (95% CI 8.0–14.6) of the patients developedADA before 18 months with the
LUC method in Austria and 4% (95% CI 0.7–7.4) with the iLite method in Sweden.
Results for natalizumab. In the univariate analysis of the pooled data from Sweden, Den-
mark and Austria, 6.0% [5.1–6.8] of the patients developed anti-natalizumab ADA. As
expectedmost of the ADA occurredwithin six months of natalizumab therapy. The country
was associated with occurrence of ADA (p = 0.004) (Fig 3).
In Sweden 4.6% (95% CI 3.7–5.9) of the patients developedADA before six months of ther-
apy, while 7.2% (95% CI 5.0–8.9) and 7.7% (95% CI 5.3–9.8) did in Denmark and Austria
respectively (Table 2).
Age at start of natalizumab therapy was associated with ADA occurrence (p = 0.03). Among
patients older than 45 years, 7.5% (95% CI 4.9–9.5) had a detectable immunogenicity at six
months of therapy compared to 5.5% (95% CI 4.6–6.5) of the younger patients.
Sex was significantly associated with ADA occurrence (p = 0.03). More female patients
(6.6%, 95% CI 5.6–7.8) have measurable ADA than males (4.5%, 95% CI 3.2–5.9) at six months
of therapy.
None of the months of natalizumab therapy start and none of the months of birth were
associated with ADA production when the countries were analyzed separately. However in the
pooled analysis, patients starting the therapy in November had a higher risk of developing
ADA (S3 and S4 Tables).
Fig 3. Cumulative probability of developing anti-natalizumab ADA. Estimated cumulative probability of
developing anti-natalizumab ADA by categorical variables with p-values for rank-based tests adapted for interval
censoring.
doi:10.1371/journal.pone.0162752.g003
Table 2. Estimated cumulative probabilities of ADA development before six months of natalizumab
therapy.
(N = 3440)
n % 95% CI
Country Sweden 1618 4.6 [3.7–5.9]
Denmark 1113 7.2 [5.0–8.9]
Austria 709 7.7 [5.3–9.8]
Age at 18–45 2585 5.5 [4.6–6.5]
baseline 45+ 855 7.5 [4.9–9.5]
Sex Female 2453 6.6 [5.6–7.8]
Male 987 4.5 [3.2–5.9]
doi:10.1371/journal.pone.0162752.t002
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None of the variables characterizing previous IFNβ therapy (last IFNβ taken, first IFNβ
taken, last ADA status during IFNβ therapy, total duration of IFNβ therapy and number of dif-
ferent IFNβ therapies) was significantly associated with development of ADA against natalizu-
mab (S1 Fig).
Multivariate analyses
Results for IFNβ. Type of IFNβ, age at start of therapy, sex and month of therapy start
were included in a multivariate Cox regression model for each cohort and results are reported
in Table 3 and Fig 4.
As the ADA assay method was acting as a confounding factor for the Swedish and Austrian
cohorts, we adjusted for this variable in the Cox model. The adjusted hazard ratios (HR) varied
from 4.9 to 7.8 for IFNβ-1a s.c. compared to IFNβ-1a i.m. (95% CI ranging from 2.9 to 20.0)
and from 6.4 to 10.4 for IFNβ-1b s.c. compared to IFNβ-1a i.m. (95% CI ranging from 3.2 to
25.9) (Table 3 and Fig 4).
HRs relative to age older than 50 compared to age between 18 and 30 varied from 1.3 to 1.9
across the cohorts (95% CI ranging from 0.8 to 3.8) (Table 3 and Fig 4).
The adjusted HRs for males compared to females were significant in Austria (1.4, 95% CI 1.1–
1.9) and Denmark (1.6, 95% CI 1.0–2.7), at the limit of significance in Germany-Dusseldorf (1.4,
95% CI 0.9–2.0) and not significant in Sweden (1.0, 95% CI 0.7–1.3) (Table 3 and Fig 4).
After adjustment for other risk factors, start of therapy in April compared to start in any
other month was still a risk factor for ADA development in Sweden (1.6, 95% CI 1.1–2.4) and
Germany (Dusseldorf)(2.4, 95% CI 1.5–3.9), and was associated with a lower risk in Austria
(0.6, 95% CI 0.3–1.0) (Table 3 and Fig 4).













(N = 1830) (N = 1632) (N = 1082) (N = 618) (N = 437) (N = 5638)
HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Type of IFNβ IFN-1a i.m. 1.0 reference 1.0 reference 1.0 reference 1.0 reference 1.0 reference 1.0 reference
IFN-1a s.c. 7.6 [4.6–12.6] 4.9 [3.1–8.0] 7.8 [3.1–20.0] 5.1 [2.9–8.8] 10.3 [1.3–79.3] 6.4 [4.9–8.4]
IFN-1b s.c. 9.7 [5.9–15.8] 6.4 [3.9–10.2] 10.4 [4.2–25.9] 6.8 [3.2–14.5] 31.2 [4.2–229.5] 8.7 [6.6–11.4]
Age at baseline 18–30 1.0 reference 1.0 reference 1.0 reference 1.0 reference 1.0 reference 1.0 reference
30–40 1.1 [0.7–1.6] 1.3 [0.9–1.9] 1.1 [0.7–1.7] 0.6 [0.3–1.2] 0.6 [0.3–1.4] 1.1 [0.8–1.3]
40–50 1.3 [0.8–1.9] 2.0 [1.4–2.9] 0.8 [0.5–1.4] 1.0 [0.5–2.0] 1.3 [0.6–2.6] 1.3 [1.1–1.6]
50+ 1.7 [1.1–2.6] 1.8 [1.1–2.9] 1.3 [0.8–2.4] 1.9 [0.9–3.8] 1.5 [0.6–3.9] 1.8 [1.4–2.3]
Sex Female 1.0 reference 1.0 reference 1.0 reference 1.0 reference 1.0 reference 1.0 reference
Male 1.0 [0.7–1.3] 1.4 [1.1–1.9] 1.4 [0.9–2.0] 1.6 [1.0–2.7] 2.4 [1.4–4.2] 1.3 [1.1–1.6]
Month of start Other months 1.0 reference 1.0 reference 1.0 reference 1.0 reference 1.0 reference 1.0 reference
April 1.6 [1.1–2.4] 0.6 [0.3–1.0] 2.4 [1.5–3.9] 1.2 [0.6–2.7] 2.2 [0.9–5.3] 1.3 [1.0–1.6]
Assay MPA 1.0 reference 1.0 reference
method MGA 0.3 [0.2–0.5] 0.5 [0.3–0.9]
LUC 0.8 [0.6–1.0]
iLite 0.2 [0.1–0.3]
*Analysis adjusted on the country
doi:10.1371/journal.pone.0162752.t003
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According to the analysis of the pooled dataset of the five cohorts we found similar associa-
tions with type of treatment (HR = 6.4 [4.9–8.4] for IFNβ-1a s.c. and 8.7 [6.6–11.4] for IFNβ-
1b s.c. both versus IFNβ-1a i.m.), age (HR = 1.8 [1.4–2.3] for patients older than 50 versus 18–
30), sex (HR = 1.3 [1.1–1.6] for males versus females), month of therapy start (HR = 1.3 [1.0–
1.6] for April compared to other months) (Table 3).
Results for natalizumab. Age at start of natalizumab therapy and sex were analyzed
together with a Cox regression model for each cohort and for the pooled dataset with adjust-
ment on the country (Table 4 and Fig 5). The two variables were identified as risk factors for
ADA occurrence in the pooled cohort, whereas the associations with ADA development were
not statistically significant in each individual cohort.
Fig 4. Multivariate risk factors for anti-IFNβ ADA development. Multivariate risk factors for anti-IFNβ ADA
development in each cohort, adjusted on assay method at the last visit in Sweden and Austria.
doi:10.1371/journal.pone.0162752.g004
Table 4. Adjusted hazard ratios for risk factors of anti-natalizumab ADA development.
Sweden Denmark Austria Pooled*
(N = 1618) (N = 1113) (N = 709) (N = 3440)
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Age at 18–45 1.0 reference 1.0 reference 1.0 reference 1.0 reference
baseline > = 45 1.2 [0.7–2.0] 1.4 [0.9–2.2] 1.6 [0.8–3.0] 1.4 [1.0–1.8]
Sex Female 1.0 reference 1.0 reference 1.0 reference 1.0 reference
Male 0.7 [0.4–1.3] 0.8 [0.5–1.3] 0.6 [0.3–1.2] 0.7 [0.5–0.98]
*Analysis adjusted on the country
doi:10.1371/journal.pone.0162752.t004
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HRs for age older than 45 at start of therapy compared to age 18–45 varied from 1.2 to 1.6
across the cohorts (95% CI ranging from 0.7 to 3.0) and was 1.4 (95% CI 1.0–1.8) over all the
cohorts pooled together.
The HR for men compared to women was 0.7 (95% CI 0.4–1.3) in Sweden, 0.8 (95% CI 0.5–
1.3) in Denmark and 0.6 (95% CI 0.3–1.2) in Austria. In the pooled dataset, it was 0.7 (95% CI
0.5–0.98) (Table 4 and Fig 5).
Discussion
To the best of our knowledge, this is the first collaborative cohort analysis investigating the
impact of patient characteristics and type of BPs on the occurrence of ADA inMS. In order to
carry out an unbiased evaluation of the relationships between bio-clinical factors and the
occurrence of ADAs, we have selected a target population which was extracted from the whole
ABIRISK database. This selected population is composed by naive adult patients with biologi-
cal samples being taken within the first two years of treatment. From this selected population
which combines data from four national European reference laboratories and one research
center, we report that the occurrence of ADA against BPs used to treat MS (IFNβ and natalizu-
mab) were associated with age and sex. Older patients were at higher risk of developing ADA
against both IFNβ and natalizumab. In contrast, the sex effect differs between the two BPs,
with male patients beingmore at risk of anti-IFNβADA and female patients more at risk of
anti-natalizumab ADA.
We confirm the previously reported differences in the cumulative probability of ADA
occurrence at 18 months of treatment for the different types of IFNβ (ranging between 1.1–
4.2% for IFNβ-1a i.m., 11.1–23.0% for IFNβ-1a s.c. and 17.4–33.3% for IFNβ-1b s.c. in the pres-
ent study) [1].
Interestingly, we also observe that patients who started IFNβ therapy in the month of April
showed a higher risk of ADA development. This relationship is not seen in every cohort but
Fig 5. Multivariate risk factors for anti-natalizumab ADA development. (N = 3440).
doi:10.1371/journal.pone.0162752.g005
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stays significant in the German (Dusseldorf)and in the Swedish cohorts after adjustment for
multiple testing.We do not find a relationship betweenADA occurrence and the month of
birth neither for IFNβ nor for natalizumab-treated patients. In the latter, no factor related to
previous IFNβ exposure (last IFNβ taken, first IFNβ taken, last ADA status during IFNβ ther-
apy, total duration of IFNβ therapy and number of different IFNβ therapies) is associated to
anti-natalizumab ADA development.
Since this study relies on historical cohorts, we had to cope with various follow-up schemes.
For example, in Sweden and Denmark the assays were done routinely, while in Germany the
testing was left to the discretion of the treating physician. However, from a previous study, the
characteristics of the patients who have been tested due to an indication of worsening disease
and therefore a suspicion of ADA did not differ significantly in ADA frequency from those
that were tested according to regular routine dates [27]. Moreover, in our analyses we observed
similar follow-up schemes by age and sex.
In this study, we do not know the exact time of ADA occurrence but we know whether or
not ADA has occurredwithin a monitoring interval. These so-called interval censored data
have often been analyzed with various ad-hoc solutions such as the use of either the right-sided
endpoint for subject with positive ADA or the midpoint in the interval. These solutions are
known to be non-optimal and biased when the times between visits are long or the frequency
of ADA assessment varies in the population which is the case in our study that included various
cohorts with different follow-up scheme. Here, all the analyses were performed using method-
ologies designed for such interval-censoreddata.
In this study, it is worth noting that different types of assay were sequentially used over time
and that these differencesmight have reflected changes in treatment choice over time or
changes in treatment formulation as for the IFNβ-1a s.c. in 2007 [17]. We cannot assess the
effect of change in IFNβ-1a s.c. formulation as its date is too close to the date of change in type
of assay used. Nevertheless when we adjusted on the type of IFNβ treatment in the multivariate
analyses, differences between the assay methods in terms of ADA development remained sig-
nificant, suggesting that assay methodsmay differ in sensitivity of ADA detection as previously
reported [18].
Due to the wide range of ADA detection process for IFNβ, the analyses were initially per-
formed separately on each country. Access to reference laboratory data enabled us to have suf-
ficient number of patients in each country that gave us sufficient power to detect the
association of interest if it existed. Since we did not observe discrepancies between the results
obtained for each country, we then also performed the multivariate analysis on the pooled
cohort.
For natalizumab, since the same assay methodwas used and the laboratories had been tested
yearly for concordant test results of 20 samples (personal communication from A. Fogdell-
Hahn), the univariate analysis was applied on the pooled cohort. As we observed a country
effect,multivariate analysis was performed both on separate and pooled cohort.
Our selection criteria implied that we includedmore patients who began their treatment
more recently. This led for instance to the fact that our study population includes more IFNβ-
1a i.m. treated patients than the global ABIRISK database. Because of the differences between
included and excluded patients in terms of type of treatment, age at first treatment or first
ADA status, our study population might not be representative of the general population of the
IFNβ-treated or natalizumab-treated and ADA tested MS patients. This necessary selection in
order to cope with the two-year ADA occurrencewindow could influence the global prevalence
of ADA development, but not the tests of comparisons between groups and the measure of
associations between potential risk factors and ADA development. Another consequence of the
selection is that we might lose power in some less represented subcategories. For instance,
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older patients in Germany (Dusseldorf)were less included because it might have beenmore
difficult to track their date of first dose, which may explain why the association with age could
not be seen.
The differences among treatments that we observedwere in the same range and in the same
direction as those described in previous studies [1]. The higher immunogenicity of IFNβ-1b
compared to IFNβ-1a has been attributed to its lack of glycosylation which makes it highly
prone to form aggregates. This has been confirmed in an animal model, where aggregated
IFNβ-1b and IFNβ-1a induced higher ADA seroprevalence than non-aggregated IFNβ-1a [28].
Animal studies have also suggested that both a T-independent and a T-dependent response
might contribute to IFNβ-1b immunogenicity, where the T-independent response is character-
ized by low ADA titers and low ADA persistency due to lack of a memory response [29]. Con-
versely, IFNβ-1a immunogenicity, although less frequent, generates higher titer and persistent
ADA responses, often with a neutralizing activity [15,21]. In our study as in previous ones,
although risk of ADA occurrencewas higher in IFNβ-1b s.c. treated MS-patients than in IFNβ-
1a i.m. treated, the difference with IFNβ-1a s.c.-treated was not significant.
We found a significantly higher immunogenicity of both IFNβ and natalizumab in older
patients. The impact of age was assessed in previous studies but was not found to be associated
with ADA development [30,31]. However a higher median age was observed in ADA positive
compared to ADA negative patients in one study (45 years versus 43 years, p<0.0001,
n = 1115) [15]. The negative studies had lower number of patients (n = 301 and n = 541) and
may have lacked in power to detect the association.
As thymic function declines after puberty, the main source of naïve T cells to counterbal-
ance T-cell turnover in adult life comes from their homeostatic proliferation [32]. Mathemati-
cal models corroborated by experimental data postulate that in spite of T-cell turnover,
homeostatic mechanisms keep a constant T-cell pool and the maintenance of T-cell repertoire
diversity is IL7- and TCR-dependent [33–35]. Continuous loss of senescent T-cells and conver-
sion of naïve T cells into memory T cells due to pathogen exposure progressively induce a
reduction of the naïve T-cell repertoire diversity and lymphopenia with a consequent decrease
in adaptive immune responses against novel antigens and increase in homeostatic proliferation
in the elderly [36]. The lymphopenic condition is known to induce a stronger proliferation of
high affinity autoreactive effector T cells to self-antigens, and if not compensated by an appro-
priate proliferation or novel thymic production of regulatory T cells it may easily lead to devel-
opment of autoimmune responses [37]. Interestingly, more than 50% of alemtuzumab-treated
MS-patients experience secondary autoimmune manifestations as a consequence of lymphope-
nia, and development of autoimmunity is strongly associated with insufficient recovery of thy-
mopoiesis after a strong initial homeostatic proliferation [38]. Similarly, lymphopenia induced
autoimmunity might explain the increased risk of anti-IFNβADA development in older MS-
patients: chronic stimuli with IFNβmight induce homeostatic proliferation of effector T cells
against a self-antigen not paralleled by an appropriate thymopoiesis of novel regulatory T cells.
In this study we identify a significant association of sex with ADA occurrence,with men
beingmore susceptible to develop IFNβADA. In one study about immunogenicity of IFNβ in
MS, it was observed that a higher proportion of female than male patients becameADA posi-
tive after 12 months of treatment with IFNβ-1a subcutaneously [39]. Later this result was not
confirmed as sex was not a predictor of development of neutralizing antibodies in clinical data
collected prospectively in Denmark [31]. Apart from these studies, the association between
sex-related factors and ADA development has not been investigated so far. Their characteriza-
tion is of utmost importance since some of these factors may be controlled (e.g. oral contracep-
tion, breastfeeding) for prevention of ADA development. A thorough knowledge of X-linked
genetic factors, hormonal factors and behavioral factors is needed to distinguish which sex- (or
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gender-) specific factor mostly contributes to this difference. Among interesting gene candi-
dates encoded on the X-chromosome are several transcription factors such as FOXP3 and
immunity receptors such as TLR7 and TLR8. Sex hormones are important modulators of
immune responses and several autoimmune diseases display a sex bias with a higher prevalence
in women [40]. The hormonal status of the patient at therapy start is therefore likely to influ-
ence the development of ADA. Interestingly the sex difference in IFNβADA occurrencewas
observed in all the analyzed European countries except Sweden. A hypothesis to account for
this peculiaritymight be a local behavioral difference influencing a relevant exposure such that
the exposure would be similar in men and women in Sweden, but higher in men in the other
countries.
Concerning natalizumab, inversely to IFNβ, we observed that women developedADA more
often than men. IFNβ being a cytokine and natalizumab a monoclonal antibody, they are struc-
turally different and might have distinct immunogenicity mechanisms. A slower pharmacoki-
netics in women than in men has been reported for several drugs, including the TNFα-
blockingmonoclonal antibody adalimumab [41], and might induce a prolonged exposure to
the drug in women with possible effects on immunogenicity. The early pharmacokinetics study
on natalizumab did not analyze the influence of sex [42], and a sex difference in natalizumab
clearance warrants further investigation.
An association of month of birth with risk of developingMS has clearly been established in
several case-control studies from the Northern and Southern hemisphere, albeit with a small
effect size [43]. In the Northern hemisphere individuals born in April-May carry a higher risk
of MS, whereas individuals born in October-November display a slight protection fromMS.
The month of birth effect is thought to derive from fetal exposure to a seasonal factor in the
last trimester of pregnancy, a crucial period in the negative selection of autoreactive T cells in
the fetal thymus [44]. As ADA (in particular against IFNβ) may be considered an autoimmune
phenomenon, we investigated whether a month of birth effect could be linked also to ADA
occurrence, but we were not able to detect an association. Considering the small effect size
which has been reported for the association betweenmonth of birth and MS (OR = 1.08 for
May in a UK case-control study [45]), we did not have the power to detect a similarly small
effect in our study.
Instead we observed a significant association of the month of therapy start with IFNβADA
in Sweden, Germany (Dusseldorf group), Austria, and borderline significant in Germany
(Munich group). For all the cohorts the month associated with ADA was April, but surpris-
ingly start in April conferred an increased risk in all the cohorts except Austria, where it con-
ferred decreased risk. Further investigations are warranted to confirm this association and to
identify the underlying seasonal factor. Candidate seasonal factors which might influence the
immune status at start of therapy are allergy causing spring pollens or early spring vitamin D
insufficiency.
Vitamin D is a modulator of T- and B-cell responses [46], and genetically and environmen-
tally determined vitamin D insufficiency is a risk factor for MS [47,48]. B-lymphocytes express
the VDR and vitamin D is able to suppress their proliferation, immunoglobulin production,
class switch and differentiation to plasma cells [49], thus it might play a role in ADA develop-
ment. It has been suggested that part of the effect of IFNβ is mediated by induction of vitamin
D synthesis [50]. From these results and from the previous knowledge of the immunomodula-
tory activity of vitamin D it could be hypothesized that vitamin D levels at start of therapy,
influenced by the seasonal UV-radiation and possibly also by early response to IFNβ therapy,
is a factor associated with ADA development. Several randomized controlled clinical trials on
vitamin D supplementation to IFNβ or glatiramer therapy in MS are ongoing [51,52]. Studies
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to correlate vitamin D levels before and during IFNβ therapy with later ADA development are
warranted.
In conclusion, the findings obtained from this consortium cohort provide new insights on
ADA occurrence.Age and sex were found to be risk factors of ADA development against IFNβ
and natalizumabMS therapies in data from four national European reference laboratories and
one research study. We also observed an association with the month of start of therapy which
warrants further investigation. The next step of our research project, which is currently ongo-
ing, is to include data from additional MS registries and research study questionnaires to assess
other potential explanatory factors such as vitamin D serum levels, previous and concomitant
medications, medical history, infections, vaccinations, tobacco consumption and genetic fac-
tors. The effect size of the associations with age and sex were not high enough to discourage cli-
nicians in terms of drug prescription, but a more frequent ADA monitoring is recommended
for the risk groups to allow earlier detection of ADA and an appropriate drug switch.
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